Core Viewpoint - The company has received approval for a new veterinary drug, a genetically engineered subunit vaccine for Clostridium chauvoei (Type A), aimed at preventing sudden death in cattle caused by this pathogen [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., has collaborated with other companies to develop the new veterinary drug [1] - The approval was granted by the Ministry of Agriculture and Rural Affairs of China, following the review of the National Veterinary Drug Administration regulations [1] Group 2: Product Details - The vaccine is designed to prevent sudden death syndrome in cattle caused by Type A Clostridium chauvoei [1] - Immunity is achieved within 7 days post-second vaccination, with an immunity duration of 5 months [1]